<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Almanac of Clinical Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Almanac of Clinical Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Альманах клинической медицины</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2072-0505</issn><issn publication-format="electronic">2587-9294</issn><publisher><publisher-name xml:lang="en">Moscow Regional Research and Clinical Institute (MONIKI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">14</article-id><article-id pub-id-type="doi">10.18786/2072-0505-2013-28-72-78</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SCIENTIFIC REVIEWS, LECTURES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАУЧНЫЕ ОБЗОРЫ, ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">METHODS OF EXTRACORPOREAL HEMOCORRECTION IN COMPLEX TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AFTER KIDNEY TRANSPLANTATION</article-title><trans-title-group xml:lang="ru"><trans-title>МЕТОДЫ ЭКСТРАКОРПОРАЛЬНОЙ ГЕМОКОРРЕКЦИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ БАКТЕРИАЛЬНЫХ И ВИРУСНЫХ ИНФЕКЦИЙ ПОСЛЕ ТРАНСПЛАНТАЦИИ ПОЧКИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vatazin</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Ватазин</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Astakhov</surname><given-names>P. V.</given-names></name><name xml:lang="ru"><surname>Астахов</surname><given-names>П. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zulkarnaev</surname><given-names>A. B.</given-names></name><name xml:lang="ru"><surname>Зулькарнаев</surname><given-names>А. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Krstic</surname><given-names>M.</given-names></name><name xml:lang="ru"><surname>Крстич</surname><given-names>М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kantaria</surname><given-names>R. O.</given-names></name><name xml:lang="ru"><surname>Кантария</surname><given-names>Р. О.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedulkina</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Федулкина</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского  (МОНИКИ)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2013</year></pub-date><issue>28</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>72</fpage><lpage>78</lpage><history><date date-type="received" iso-8601-date="2016-02-10"><day>10</day><month>02</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-02-10"><day>10</day><month>02</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Vatazin A.V., Astakhov P.V., Zulkarnaev A.B., Krstic M., Kantaria R.O., Fedulkina V.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Ватазин А.В., Астахов П.В., Зулькарнаев А.Б., Крстич М., Кантария Р.О., Федулкина В.А.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Vatazin A.V., Astakhov P.V., Zulkarnaev A.B., Krstic M., Kantaria R.O., Fedulkina V.A.</copyright-holder><copyright-holder xml:lang="ru">Ватазин А.В., Астахов П.В., Зулькарнаев А.Б., Крстич М., Кантария Р.О., Федулкина В.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://almclinmed.ru/jour/article/view/14">https://almclinmed.ru/jour/article/view/14</self-uri><abstract xml:lang="en"><p>Scientific publications devoted to the contemporary prospective selected and combined extracorporeal modalities to treat complications after renal allotransplantation were analyzed involving pyoseptic processes and viral hepatites.</p></abstract><trans-abstract xml:lang="ru"><p>Анализируются работы, посвященные современным перспективным селективным и комбинированным экстракорпоральным методам лечения осложнений после аллотрансплантации почки – гнойно-септических процессов и вирусных гепатитов. </p></trans-abstract><kwd-group xml:lang="en"><kwd>sepsis</kwd><kwd>septic complications</kwd><kwd>viral hepatitis</kwd><kwd>kidney transplantation</kwd><kwd>hemofiltration</kwd><kwd>cytokine sorption</kwd><kwd>sorption of endotoxin</kwd><kwd>plasmapheresis</kwd><kwd>cascade plasma filtration</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сепсис</kwd><kwd>гнойно-септические осложнения</kwd><kwd>вирусный гепатит</kwd><kwd>трансплантация почки</kwd><kwd>гемо-фильтрация</kwd><kwd>сорбция цитокинов</kwd><kwd>сорбция эндотоксина</kwd><kwd>плазмаферез</kwd><kwd>каскадная плазмофильтрация</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.Введенский Д.В., Кирковский В.В., Голубович В.П. и др. Клиническая эффективность биоспецифического гемо-сорбента «Липосорб» // Вестн. РАМН. 2009. №10. С.40-43.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.Хорошилов С.Е., Карпун Н.А., Половников С.Г. и др. Селективная гемосорбция эндотоксина в лечении абдоминального сепсиса // Общая реаниматология. 2009. №6. С.83-87.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.Antonelli M., Fumagalli R., Cruz D.N. et al. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial // Contrib. Nephrol. 2010. V.167. P.83-90.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.Bellomo R., Tetta C., Ronco C. Coupled plasma filtration adsorption // Intensive Care Med. 2003. V.29, No.8. P.1222-1228.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.Berlot G., Bianco N., Tomasini A. et al. Changes in microvascular blood flow during coupled plasma filtration and adsorption // Anaesth. Intens. Care. 2011. V.39, No.4. P.687-689.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.Braks R.E., Ganne-Carrie N., Fontaine H. et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin // World J. Gastroenterol. 2007. V.13, No.42. P.5648-5653.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.Cardoso A.C., Moucari R., Figueiredo-Mendes C. et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis // J. Hepatol. 2010. V.52, No.5. P.652-657.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.Cavaillon J.M. Polymyxin B for endotoxin removal in sepsis // Lancet Infect. Dis. 2011. V.11, No.6. P.426-427.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.Cruz D.N., Perazella M.A., Bellomo R. et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review // Crit Care. 2007. V.11, No.2. Р.47.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.Davies B., Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock // Lancet Infect. Dis. 2011. V.11, No.1. P.65-71.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.Formica M., Inguaggiato P., Bainotti S., Wratten M.L. Coupled plasma filtration adsorption // Contrib. Nephrol. 2007. No.156. P.405-410.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.Fujiwara K., Kaneko S., Kakumu S. et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load // Hepatol. Res. 2007. V.37, No.9. P.701-710.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.Hanafusa N., Kondo Y., Suzuki M. et al. Double filtration plasmapheresis can decrease factor XIII Activity // Ther. Apher. Dial. 2007. V.11, No.3. P.165-170.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.Honoré P.M., Joannes-Boyau O., Collin V. et al. Continuous hemofiltration in 2009: what is new for clinicians regarding pathophysiology, preferred technique and recommended dose? // Blood Purif. 2009. V.28, No.2. P.135-143.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.Ishikawa T., Higuchi K., Kubota T. et al. Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy // Ther. Apher. Dial. 2011. V.15, No.4. P.400-405.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.Kaneko S., Sata M., Ide T. et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C // Hepatol. Res. 2010. V.40, No.11. P.1072-1081.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.Kim S.R., Imoto S., Kudo M. et al. Double-filtration plasmapheresis plus IFN for HCV-1b patients with non-sustained virological response to previous combination therapy: early viral dynamics // Intervirology. 2010. V.53, No.1. P.44-48.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.Kondo Y., Ueno Y., Wakui Y. et al. Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients // Hepatol. Res. 2011. V.41, No.12. P.1153-1168.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19.Kushi H., Miki T. Haeoperfusion with an immobilized Plymyxin B column reduces the blood level of neutrophil elastase // Blood Purifcat. 2006. V.24. P.212-217.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20.Kushi H., Miki T., Sakagami Y. et al. Hemoperfusion with an immobilized polymyxin B fiber column decreases macrophage and monocyte activity // Ther. Apher. Dial. 2009. V.13, No.6. P.515-519.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.Kushi H., Miki T., Sakagami Y. et al. Hemoperfusion with a polymyxin B fiber column decreases clotting activity // Ther. Apher. Dial. 2009. V.13, No.6. P.528-533.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22.Mao H.J., Yu S., Yu X.B. et al. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome // Int. J. Artif. Organs. 2009. V.32, No.1. P.31-38.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23.Naka T., Shinozaki M. The effect of continuous veno-venous haemofiltration or direct hemoperfusion with Polymyxin B-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock // Ther. Apher. Dial. 2006. V.10, No.1. P.7-11.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24.Nakamura M., Oda S., Sadahiro T. et al. Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator // Contrib. Nephrol. 2010. No.166. P.73-82.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25.Namba T., Shiba R., Yamamoto T. et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy // Clin. Exp. Nephrol. 2010. V.14, No.4. P.372-376.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26.Novelli G., Ferretti G., Poli L. et al. Clinical results of treatment of postsurgical endotoxin-mediated sepsis with polymyxin-B direct hemoperfusion // Transplant. Proc. 2010. V.42, No.4. P.1021-1024.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27.Ohara T., Oteki T., Suzuki T. et al. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination // Hepatogastroenterology. 2011. V.58, No.105. P.133-136.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28.Payen D., Mateo J., Cavaillon J.M. et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial // Crit. Care Med. 2009. V.37, No.3. P.803-810.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29.Peng Z., Pai P., Hong-Bao L. et al. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients // Cytokine. 2010. V.50, No.2. P.186-191.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30.Peng Z., Singbartl K., Simon P. et al. Blood purification in sepsis: a new paradigm // Contrib. Nephrol. 2010. No.165. P.322-328.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31.Rachoin J.S., Foster D., Dellinger R.P. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES // Contrib. Nephrol. 2010. No.167. P.111-118.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32.Ramasubban S., Majumdar A., Das P.S. Safety and efficacy of polymyxin B in multidrug resistant Gram-negative severe sepsis and septic shock // Indian J. Crit. Care Med. 2008. V.12, No.4. P.153-157.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33.Ronco C., Piccinni P., Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique // Contrib. Nephrol. 2010. No.167. P.25-34.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34.Sakamoto Y., Mashiko K., Obata T. et al. Effectiveness of continuous hemodiafiltration using a polymethylmethacry-late membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock // ASAIO J. 2008. V.54, No.1. P.129-132.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35.Sato K., Maekawa H., Sakurada M. et al. Direct hemoper-fusion with polymyxin B immobilized fiber for abdominal sepsis in Europe // Surg. Today. 2011. V.41, No.6. P.754-760.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36.Shimizu T., Hanasawa K., Sato K. et al. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation // Langenbecks Arch. Surg. 2009. V.394, No.2. P.303-311.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37.Stengl M., Sykora R., Chvojka J. et al. Differential effects of hemofiltration and of coupled plasma filtration adsorption on cardiac repolarization in pigs with hyperdynamic septic shock // Shock. 2010. V.33, No.1. P.101-105.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38.Sykora R., Chvojka J., Krouzecky A. et al. Coupled plasma filtration adsorption in experimental peritonitis-induced septic shock // Shock. 2009. V.31, No.5. P.473-480.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39.Takada Y., Ito T., Ueda Y. et al. Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation // Liver Transpl. 2008. V.14, No.7. P.1044-1047.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40.Taniguchi M., Furukawa H., Shimamura T. et al. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C // Transplantation. 2006. V.81, No.12. P.1747-1749.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41.Taniguchi T. Cytokine adsorbing columns // Contrib. Nephrol. 2010. No.166. P.134-141.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42.Wong J.B., Davis G.L., McHutchison J.G. et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C // Am. J. Gastroenterol. 2003. V.98, No.11. P.2354-2362.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43.Yamashita T., Arai K., Sakai A. et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study // Hepatol. Res. 2006. V.36, No.3. P.167-175.</mixed-citation></ref></ref-list></back></article>
